News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ambit Biosciences Announces Participation At Oppenheimer 24th Annual Healthcare Conference



12/5/2013 6:24:09 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Oppenheimer 24th Annual Healthcare Conference to be held at the Crown Plaza Hotel in New York City, December 10-11, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, Quizartinib, at 3:55 p.m. PT/ 12:55 p.m. ET on Wednesday, December 11th, 2013. The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com. An audio replay will be available for 30 days following the initial presentation webcast.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Ambit Contacts:

Marcy Graham

Ian Stone/David Schull

Executive Director, Investor Relations & Corp Comm

Media Contacts

Ambit Biosciences, Inc.

Russo Partners

858-334-2125

619-308-6541/212-845-4271

mgraham@ambitbio.com

ian.stone@russopartnersllc.com/david.schull@russopartnersllc.com

SOURCE Ambit Biosciences



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES